Skip to content
Bored Studies
RecruitingPhase 2

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Artiva Biotherapeutics, Inc. · NCT06991114

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
90
US sites recruiting
31
Study start
July 9, 2025
Record last updated
July 31, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.

Being studied: Allogeneic NK Cells

Conditions: Refractory Rheumatoid Arthritis (RA); Idiopathic Inflammatory Myopathies (IIMs); Systemic Sclerosis (SSc); Rheumatoid Arthritis (RA; IIM; Myositis; Scleroderma; Sjogren Syndrome; Sjogrens Disease

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

For Subjects with Refractory Rheumatoid Arthritis (RA):

  • Documented diagnosis of RA, meeting the 2010 ACR/EULAR classification criteria.
  • Rheumatoid Factor (RF) or Anti Citrullinated Protein Antibody (ACPA) positive.
  • High-sensitivity C-reactive protein (hs-CRP) > 3 mg/L or Erythrocyte Sedimentation Rate (ESR) > 28 mm/hr.
  • Have had prior treatment for a period of at least 12 weeks with a biologic disease modifying anti-rheumatic drug and were deemed refractory by the treating physician.
  • Minimum of six swollen joint counts (SJC) and six tender joint counts (TJC) according to joint assessment.

For subjects with Sjögren's Disease (SjD)

  • Prior diagnosis of Primary SjD as per 2016 ACR/EULAR criteria with confirmatory diagnosis in the 24 weeks preceding screening.
  • Total Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (clinESSDAI) > 6.
  • Salivary Flow Rate > 0.1 mL/min on stimulation.

For subjects with Idiopathic Inflammatory Myopathies (IIMs)

  • Presence of a positive autoantibody (ANA >1:80 or RNP or SSA/SSB or other myositis specific autoantibodies.
  • Refractory IIM as defined by inadequate response/intolerance to at least 3 months of glucocorticoids and/or at least one other immunosuppressive.
  • Muscle biopsy or muscle MRI to confirm IIM diagnosis, where applicable, within 12 months prior to enrollment.

For Subjects with Systemic Sclerosis (SSc)

  • Diagnosis of SSc in accordance with the ACR/EULAR 2013 classification.
  • Modified Rodnan skin score (mRSS) > 10.
  • Initial confirmatory diagnosis within 8 years of screening.
  • Refractory SSc as defined by inadequate response/intolerance to at least 3 months of glucocorticoids and/or at least one other immunosuppressive.

Recruiting US locations

Study contacts (from the official record)

  • Chanel Mansfield Director, Clinical Operations, MPH · 1 858 223 7001 · clinicaltrials@artivabio.com
All arthritis studies in Alabama →
AlloNK®, an Allogeneic Non-genetically Modified, Cord… (NCT06991114) | Bored Studies